Oncology Medical News about Caspofungin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Caspofungin for the treatment of candidaemia in patients with haematological malignancies
Clinical Microbiology and Infection, 07/01/09

Pagano L et al. - In a study to evaluate the efficacy of caspofungin in neutropenic pts with haematological malignancies (HM) and candidaemia, results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.

Methods

This study was prospectively conducted in 11 haematology divisions over a 2-yr period to evaluate the efficacy of caspofungin in 24 neutropenic pts with haematological malignancies (HM) and candidaemia.

Results

Pts had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 109/L) for a median of 12 days (2–41) before candidaemia.
Pts received caspofungin for a median duration of 12 days, obtaining a favourable overall response of 58%.
At 30 days, 11 pts had died (46%); candidaemia was responsible for mortality in 6 pts (25%).

<< Previous
Cytoreductive surgery and hyperthermic intraperitoneal...

Next >>
Antiangiogenic strategies for treatment of malignant gliomas